Cited by 1,419SARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research StudiesSARS-CoV-2 detection and testing

The DOI matches its Crossref record; 75 of the 76 references it cites were found in a registry or an index, and 1 are not checked yet.

Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans

Open access

Seow, Jeffrey, Graham, Carl, Merrick, Blair, Acors, Sam, Pickering, Suzanne, Steel, Kathryn J. A., Hemmings, Oliver, O’Byrne, Aoife, Kouphou, Neophytos, Galao, Rui Pedro, Betancor, Gilberto, Wilson, Harry D., Signell, Adrian W., Winstone, Helena, Kerridge, Claire, Huettner, Isabella, Jimenez-Guardeño, Jose M., Lista, Maria Jose, Temperton, Nigel, Snell, Luke B., Bisnauthsing, Karen, Moore, Amelia, Green, Adrian, Martinez, Lauren, Stokes, Brielle, Honey, Johanna, Izquierdo-Barras, Alba, Arbane, Gill, Patel, Amita, Tan, Mark Kia Ik, O’Connell, Lorcan, O’Hara, Geraldine, MacMahon, Eithne, Douthwaite, Sam, Nebbia, Gaia, Batra, Rahul, Martinez-Nunez, Rocio, Shankar-Hari, Manu, Edgeworth, Jonathan D., Neil, Stuart J. D., Malim, Michael H., Doores, Katie J.·2020·Nature Microbiology

DOI 10.1038/s41564-020-00813-8PMC PMC7610833

Published version of a preprint

Open this paper in CoChat — free account Open PDF

Abstract

Antibody responses to SARS-CoV-2 can be detected in most infected individuals 10-15 d after the onset of COVID-19 symptoms. However, due to the recent emergence of SARS-CoV-2 in the human population, it is not known how long antibody responses will be maintained or whether they will provide protection from reinfection. Using sequential serum samples collected up to 94 d post onset of symptoms (POS) from 65 individuals with real-time quantitative PCR-confirmed SARS-CoV-2 infection, we show seroconversion (immunoglobulin (Ig)M, IgA, IgG) in >95% of cases and neutralizing antibody responses when sampled beyond 8 d POS. We show that the kinetics of the neutralizing antibody response is typical of an acute viral infection, with declining neutralizing antibody titres observed after an initial peak, and that the magnitude of this peak is dependent on disease severity. Although some individuals with high peak infective dose (ID 50 > 10,000) maintained neutralizing antibody titres >1,000 at >60 d POS, some with lower peak ID 50 had neutralizing antibody titres approaching baseline within the follow-up period. A similar decline in neutralizing antibody titres was observed in a cohort of 31 seropositive healthcare workers. The present study has important implications when considering widespread serological testing and antibody protection against reinfection with SARS-CoV-2, and may suggest that vaccine boosters are required to provide long-lasting protection.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1038/s41564-020-00813-8

Cites

75 of 76 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

An mRNA Vaccine against SARS-CoV-2 — Preliminary Report
Jackson, L. A., Anderson, E. J., Rouphael, N. G., Roberts, P. C., Makhene, M., Coler, R. N., McCullough, M. P., Chappell, J. D., Denison, M. R., Stevens, L. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022483 · Cited by 3,237
Antibody responses to SARS-CoV-2 in patients with COVID-19
Long, Q.-X., Liu, B.-Z., Deng, H.-J., Wu, G.-C., Deng, K., Chen, Y.-K., Liao, P., Qiu, J.-F., Lin, Y., Cai, X.-F., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0897-1 · Cited by 2,876 · cited 1×
“4) for at least 12 h; (3) Requirement for non-invasive ventilation/continuous positive airway pressure or proning or supplemental oxygen (FiO2 > 0.”
Background
Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections
Long, Q.-X., Tang, X.-J., Shi, Q.-L., Li, Q., Deng, H.-J., Yuan, J., Hu, J.-L., Xu, W., Zhang, Y., Lv, F.-J., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0965-6 · Cited by 2,686
Clinical Characteristics of 58 Children With a Pediatric Inflammatory Multisystem Syndrome Temporally Associated With SARS-CoV-2
Whittaker, E., Bamford, A., Kenny, J. M., Kaforou, M., Jones, C. E., Shah, P., Ramnarayan, P., Fraisse, A., Miller, O., Davies, P., et al. (2020) · JAMA · doi:10.1001/jama.2020.10369 · Cited by 1,996
Convergent Antibody Responses to SARS-CoV-2 in Convalescent Individuals
Robbiani, D. F., Gaebler, C., Muecksch, F., Lorenzi, J. C. C., Wang, Z., Cho, A., Agudelo, M., Barnes, C. O., Gazumyan, A., Finkin, S., et al. (2020) · Nature · doi:10.1038/s41586-020-2456-9 · Cited by 1,853
Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19
Sekine, T., Perez-Potti, A., Rivera-Ballesteros, O., Strålin, K., Gorin, J.-B., Olsson, A., Llewellyn-Lacey, S., Kamal, H., Bogdanovic, G., Muschiol, S., et al. (2020) · Cell · doi:10.1016/j.cell.2020.08.017 · Cited by 1,788
A serological assay to detect SARS-CoV-2 seroconversion in humans
Amanat, F., Stadlbauer, D., Strohmeier, S., Nguyen, T. H. O., Chromikova, V., McMahon, M., Jiang, K., Arunkumar, G. A., Jurczyszak, D., Polanco, J., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0913-5 · Cited by 1,769
Human neutralizing antibodies elicited by SARS-CoV-2 infection
Ju, B., Zhang, Q., Ge, J., Wang, R., Sun, J., Ge, X., Yu, J., Shan, S., Zhou, B., Song, S., et al. (2020) · Nature · doi:10.1038/s41586-020-2380-z · Cited by 1,667
Severe Acute Respiratory Syndrome Coronavirus 2−Specific Antibody Responses in Coronavirus Disease Patients
Okba, N. M. A., Müller, M. A., Li, W., Wang, C., GeurtsvanKessel, C. H., Corman, V. M., Lamers, M. M., Sikkema, R. S., de Bruin, E., Chandler, F. D., et al. (2020) · Emerging Infectious Diseases · doi:10.3201/eid2607.200841 · Cited by 1,614 · cited 1×
“8) and peripheral oxygen saturations <90% (with no history of type 2 respiratory failure (T2RF)) or <85% (with known T2RF) for at least 12 h; (5) Requirement for ECMO.”
Background
Development of an inactivated vaccine candidate for SARS-CoV-2
Gao, Q., Bao, L., Mao, H., Wang, L., Xu, K., Yang, M., Li, Y., Zhu, L., Wang, N., Lv, Z., et al. (2020) · Science · doi:10.1126/science.abc1932 · Cited by 1,434

Show all 62 references

Sorted by citations

Items 501–600 of 1,004

Recent Developments in SARS-CoV-2 Neutralizing Antibody Detection Methods
Ndzouboukou, J. B., Zhang, Y., & Fan, X. (2021) · Current Medical Science · doi:10.1007/s11596-021-2470-7 · Cited by 23
Endogenous Antibody Responses to SARS-CoV-2 in Patients With Mild or Moderate COVID-19 Who Received Bamlanivimab Alone or Bamlanivimab and Etesevimab Together
Zhang, L., Poorbaugh, J., Dougan, M. L., Chen, P., Gottlieb, R., Huhn, G. D., Beasley, S., Daniels, M., Trinh, T. N. V., Crisp, M., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.790469 · Cited by 25
“351 1253 (1-241; 245-1256) Wuhan spike with (L18F,D80A,D215G,del242-244, K417N,E484K, N501Y,D614G,”
Background
Multiplexed COVID-19 antibody quantification from human sera using label-free nanoplasmonic biosensors
Adi, W., Biswas, D., Shelef, M. A., & Yesilköy, F. (2022) · Biomedical Optics Express · doi:10.1364/boe.454919 · Cited by 23
Rapid quantitation of SARS-CoV-2 antibodies in clinical samples with an electrochemical sensor
Sanjay, S. T., Durr, N., Jolly, P., & Ingber, D. E. (2022) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2022.115037 · Cited by 23
“…is essential to evaluate the strength and extent of immunity generated by exposure to the virus, its variants, or the vaccines, and all this information is crucial for implementing effective public policy and vaccination strategies (Elledge et al., 2021; Jeyanathan et al., 2020; Seow et al., 2020).”
Background
Evaluation of SARS‐CoV‐2 antibody levels on hospital admission as a correlate of protection against mortality
Mink, S., List, W., Hoefle, G., Frick, M., Suessenbacher, A., Winder, T. L., Fetz, C., Bösl, A., Saely, C. H., Drexel, H., et al. (2023) · Journal of Internal Medicine · doi:10.1111/joim.13606 · Cited by 23
Longitudinal analysis of antibody response following SARS-CoV-2 infection in pregnancy: From the first trimester to delivery
Cosma, S. D., Carosso, A. R., Corcione, S., Cusato, J., Borella, F., Antonucci, M., Marozio, L., Revelli, A., Preti, M., Ghisetti, V., et al. (2021) · Journal of Reproductive Immunology · doi:10.1016/j.jri.2021.103285 · Cited by 22
Human antiviral B cell responses: Emerging lessons from hepatitis B and COVID‐19
Burton, A. R., & Maini, M. K. (2021) · Immunological Reviews · doi:10.1111/imr.12953 · Cited by 24
Neutralizing and binding antibody kinetics of COVID-19 patients during hospital and convalescent phasesPreprint
Yao, X., Liu, W. Y., Li, Z., Xiong, H., Su, Y., Li, T., Zhang, S., Zhang, X., Bi, Z., Deng, C.-X., et al. (2020) · Research Square · doi:10.21203/rs.3.rs-327912/v1 · Cited by 23
Peptide Antidotes to SARS-CoV-2 (COVID-19)Preprint
Watson, A., Ferreira, L. M. R., Hwang, P. K., Xu, J., & Stroud, R. M. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.08.06.238915 · Cited by 24
Development of SARS-CoV-2 vaccines: challenges, risks, and the way forward
Vashishtha, V. M., & Kumar, P. (2020) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2020.1845524 · Cited by 22
“Seow et al.19 studied the sequential samples of 65 RT-PCRconfirmed cases of COVID-19 and found that the IgM and IgA binding to the “S” protein declines rapidly after 20–30 days of onset of symptoms.”
BackgroundInfluential
Evaluation of SARS-CoV-2 IgG antibody reactivity in patients with systemic lupus erythematosus: analysis of a multi-racial and multi-ethnic cohort
Saxena, A., Guttmann, A., Masson, M., Kim, M., Haberman, R. H., Castillo, R., Scher, J. U., Deonaraine, K., Engel, A., Belmont, M. H., et al. (2021) · The Lancet Rheumatology · doi:10.1016/s2665-9913(21)00114-4 · Cited by 23
“…of immuno suppressants on the SARS-CoV-2 antibody response, a subset of patients with acute SARS-CoV-2 infection in the study by Seow and colleagues 24 received immuno modulating medications for a hyper-inflam matory syndrome, with no apparent impact on the neutralising antibody response, although…”
Prevalence, Persistence, and Factors Associated with SARS-CoV-2 IgG Seropositivity in a Large Cohort of Healthcare Workers in a Tertiary Care University Hospital in Northern Italy
Scozzari, G., Costa, C. S., Migliore, E., Coggiola, M., Ciccone, G., Savio, L., Scarmozzino, A., Pira, E., Cassoni, P., Galassi, C., et al. (2021) · Viruses · doi:10.3390/v13061064 · Cited by 22
“In this regard, further informative data could also be obtained by evaluating levels of neutralizing antibodies, with studies having reported their longitudinal decline [38].”
Background
People living with HIV easily lose their immune response to SARS-CoV-2: result from a cohort of COVID-19 cases in Wuhan, China
Liu, Y., Xiao, Y., Wu, S., Marley, G., Ming, F., Wang, X., Wu, M., Feng, L., Tang, W., & Liang, K. (2021) · BMC Infectious Diseases · doi:10.1186/s12879-021-06723-2 · Cited by 23
“Findings from this study extend current literature by evaluating the similarities and differences in the immune response to SARS-CoV-2 infection between PLWH and HIV-naïve patients [3, 4, 6].”
Result
Does a lack of vaccine side effects correlate with reduced BNT162b2 mRNA vaccine response among healthcare workers and nursing home residents?
Oyebanji, O. A., Wilson, B. M., Keresztesy, D., Carias, L. L., Wilk, D. J., Payne, M., Aung, H., Denis, K. S., Lam, E. C., Rowley, C. F., et al. (2021) · Aging Clinical and Experimental Research · doi:10.1007/s40520-021-01987-9 · Cited by 20
Longevity of anti-spike and anti-nucleocapsid antibodies after COVID-19 in solid organ transplant recipients compared to immunocompetent controls
Søfteland, J. M., Gisslén, M., Liljeqvist, J., Friman, V., de Coursey, E., Karason, K., Ekelund, J., Felldin, M., Magnusson, J. M., Baid‐Agrawal, S., et al. (2021) · American Journal of Transplantation · doi:10.1111/ajt.16909 · Cited by 22
Neutralizing antibody responses over time in demographically and clinically diverse individuals recovered from SARS-CoV-2 infection in the United States and Peru: A cohort study
Karuna, S., Li, S. S., Grant, S., Walsh, S. R., Frank, I., Casapía, M., Trahey, M., Hyrien, O., Fisher, L. H., Miner, M. D., et al. (2021) · PLoS Medicine · doi:10.1371/journal.pmed.1003868 · Cited by 21
“The serum nAb response in COVID-19–convalescent persons is highly variable, exhibiting approximately 1,000-fold range of titers among samples collected from recovering patients, and with approximately 20% to 30% of people mounting very weak or undetectable responses [34–43].”
BackgroundInfluential
The Comparability of Anti-Spike SARS-CoV-2 Antibody Tests is Time-Dependent: a Prospective Observational Study
Perkmann, T., Mucher, P., Perkmann‐Nagele, N., Radakovics, A., Repl, M., Köller, T., Schmetterer, K. G., Bigenzahn, J. W., Leitner, F., Jordakieva, G., et al. (2022) · Microbiology Spectrum · doi:10.1128/spectrum.01402-21 · Cited by 22
ChAdOx1 nCoV-19 vaccine elicits monoclonal antibodies with cross-neutralizing activity against SARS-CoV-2 viral variants
Seow, J., Graham, C., Hallett, S. R., Lechmere, T., Maguire, T. J. A., Huettner, I., Cox, D., Khan, H., Pickering, S., Roberts, R., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110757 · Cited by 18
Self-citation
Risk Management and other Factors Preventing Fraudulent Financial Reporting by State-Owned Enterprises in Indonesia
Novatiani, R. A., Afiah, N. N., & Soemantri, R. (2022) · Asian Economic and Financial Review · doi:10.55493/5002.v12i8.4587 · Cited by 33
“This finding shows that the implementation of good corporate governance affects the quality of financial reporting (Klai & Omri, 2011; Nuraini, Hermawan, Hubeis, & Panjaitan, 2015; Nurdiniah & Pradika, 2017; Seow et al., 2020; Zielonka et al., 2017).”
Background
Cross‐reactivity of SARS‐CoV‐2 with other pathogens, especially dengue virus: A historical perspective
Dutta, D., GHOSH, A. C., Dutta, C., Sukla, S., & Biswas, S. (2023) · Journal of Medical Virology · doi:10.1002/jmv.28557 · Cited by 22
The Interaction of Natural and Vaccine-Induced Immunity with Social Distancing Predicts the Evolution of the COVID-19 Pandemic
Good, M. F., & Hawkes, M. (2020) · mBio · doi:10.1128/mbio.02617-20 · Cited by 21
Neutralisation titres against SARS-CoV-2 are sustained 6 months after onset of symptoms in individuals with mild COVID-19
Underwood, A. P., Sølund, C. S., Fernandez-Antunez, C., Villadsen, S. L., Winckelmann, A. A., Bollerup, S., Mikkelsen, L. S., Sørensen, A.-L., Feng, S., Fahnøe, U., et al. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103519 · Cited by 23
“Importantly, the kinetics of nAb responses seen here are concordant with that of other longitudinal SARS-CoV-2 and human coronavirus studies [11-15,17-19], which may have been limited by either participant”
Influential
Rapid Hypermutation B Cell Trajectory Recruits Previously Primed B Cells Upon Third SARS-Cov-2 mRNA Vaccination
Paschold, L., Klee, B., Gottschick, C., Willscher, E., Diexer, S., Schultheiß, C., Simnica, D., Sedding, D., Girndt, M., Gekle, M., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.876306 · Cited by 21
“Given the over-time decay in antibody titers both after infection and vaccination (16, 17, 20, 25-28), we included only participants in this analysis who donated blood in a standard interval of 2-4 weeks after the last vaccination dose.”
Method
SARS-CoV-2 antibodies remain detectable 12 months after infection and antibody magnitude is associated with age and COVID-19 severityPreprint
Laing, E. D., Epsi, N. J., Richard, S. A., Samuels, E. C., Wang, W., Vassell, R. A., Ewing, D. F., Herrup, R., Sterling, S. L., Lindholm, D. A., et al. (2021) · medRxiv · doi:10.1101/2021.04.27.21256207 · Cited by 20
Potential impact of individual exposure histories to endemic human coronaviruses on age-dependent severity of COVID-19
Pinotti, F., Wikramaratna, P. S., Obolski, U., Paton, R. S., Damineli, D. S. C., Alcântara, L. C. J., Giovanetti, M., Gupta, S., & Lourenço, J. (2021) · BMC Medicine · doi:10.1186/s12916-020-01887-1 · Cited by 19
Bergamo and Covid-19: How the Dark Can Turn to Light
Perico, N., FAGIUOLI, S., Marco, F. D., Laghi, A., Cosentini, R., Rizzo, M., Gianatti, A., Rambaldi, A., Ruggenenti, P. L., Vecchia, C. L., et al. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.609440 · Cited by 22
Persistence assessment of SARS-CoV-2-specific IgG antibody in recovered COVID-19 individuals and its association with clinical symptoms and disease severity: A prospective longitudinal cohort study
Moradi, G., Bolbanabad, A. M., Ahmadi, S., Aghaei, A., Bahrami, F., Veysi, A., Kalmarzi, R. N., Shokri, A., Ghaderi, E., Mohsenpour, B., et al. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.107893 · Cited by 22
Accuracy of four lateral flow immunoassays for anti SARS-CoV-2 antibodies: a head-to-head comparative study
Jones, H. E., Mulchandani, R., Taylor‐Phillips, S., Ades, A. E., Shute, J., Perry, K. R., Chandra, N. L., Brooks, T. J. G., Charlett, A., Hickman, M., et al. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103414 · Cited by 19
“Since more severe disease is associated with increased antibody concentrations [22-24], which may be easier to detect, estimates of test sensitivity based on previously PCR-confirmed cases only are susceptible to “spectrum bias” [25,26].”
High seroprevalence for SARS-CoV-2 infection in South America, but still not enough for herd immunity!
Núñez-Zapata, S. F., Benites-Peralta, B., Mayta‐Tristán, P., & Rodriguez-Morales, A. J. (2021) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2021.07.022 · Cited by 21
Affinity Tag Coating Enables Reliable Detection of Antigen-Specific B Cells in Immunospot Assays
Köppert, S., Wolf, C., Becza, N., Sautto, G. A., Franke, F., Küerten, S., Ross, T. M., Lehmann, P., & Kirchenbaum, G. A. (2021) · Cells · doi:10.3390/cells10081843 · Cited by 19
Evaluation of sixteen ELISA SARS-CoV-2 serological tests
Jacot, D., Moraz, M., Coste, A. T., Aubry, C., Sacks, J. A., Greub, G., & Croxatto, A. (2021) · Journal of Clinical Virology · doi:10.1016/j.jcv.2021.104931 · Cited by 19
Long-Term Elevated Inflammatory Protein Levels in Asymptomatic SARS-CoV-2 Infected Individuals
Tserel, L., Jõgi, P., Naaber, P., Maslovskaja, J., Häling, A., Salumets, A., Žusinaite, E., Soeorg, H., Lättekivi, F., Ingerainen, D., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.709759 · Cited by 22
“Nevertheless, their antibody levels and T cell responses have been reported lower or declining (5, 9, 13, 14).”
Background
Low seropositivity and suboptimal neutralisation rates in patients fully vaccinated against COVID‐19 with B‐cell malignancies
Fox, T. A., Kirkwood, A. A., Enfield, L., O'Reilly, M. A., Arulogun, S. O., D’Sa, S., O’Nions, J., Kavi, J., Vitsaras, E., Townsend, W. M., et al. (2021) · British Journal of Haematology · doi:10.1111/bjh.17836 · Cited by 22
Association of HLA genotypes, AB0 blood type and chemokine receptor 5 mutant CD195 with the clinical course of COVID-19
Fischer, J., Schmidt, A. G., Bölke, E., Uhrberg, M., Keitel, V., Feldt, T., Jensen, B. O., Häussinger, D., Adams, O., Schneider, E. M., et al. (2021) · European journal of medical research · doi:10.1186/s40001-021-00560-4 · Cited by 21
“This proportion of samples exhibiting relevant virus neutralizing capacity is in line with results of a previous study in a similar cohort of convalescent COVID-19 patients [21].”
Result
Immune Responses to the ChAdOx1 nCoV-19 and BNT162b2 Vaccines and to Natural Coronavirus Disease 2019 Infections Over a 3-Month Period
Kim, J. Y., Lim, S. Y., Park, S., Kwon, J., Bae, S., Park, J. Y., Cha, H. H., Seo, M. H., Lee, H. J., Lee, N., et al. (2021) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiab579 · Cited by 21
Advances in immunotherapy for COVID-19: A comprehensive review
Masoomikarimi, M., Garmabi, B., Alizadeh, J., Kazemi, E., Jafari, A. A., Mirmoeeni, S., Dargahi, M., Taheri, N., & Jafari, R. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.107409 · Cited by 21
Potential SARS-CoV-2 vaccines: Concept, progress, and challenges
Hosseini, S. A., Zahedipour, F., Mirzaei, H., & Oskuee, R. K. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.107622 · Cited by 26
Vaccinated and Convalescent Donor–Derived Severe Acute Respiratory Syndrome Coronavirus 2–Specific T Cells as Adoptive Immunotherapy for High-Risk Coronavirus Disease 2019 Patients
Papayanni, P. G., Chasiotis, D., Koukoulias, K., Georgakopoulou, A., Iatrou, A., Gavriilaki, E., Giannaki, C., Bitzani, M., Geka, E., Tasioudis, P., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab371 · Cited by 21
“…recent findings [21], we demonstrate that the majority of donors maintained CoV-2-ST responses for ≥ 8 months postinfection, suggesting that this branch of immunity is not compromised, whereas decreasing antibodies in the same donors implicated a rather short-lived humoral immunity [19, 22].”
SARS-CoV-2 seroconversion among 4040 Egyptian healthcare workers in 12 resource-limited healthcare facilities: A prospective cohort study
Mostafa, A., Kandil, S. K., El-Sayed, M. H., Girgis, S. A., Hafez, H. M., Yosef, M., Saber, S., Ezzelarab, H., Ramadan, M., Algohary, E., et al. (2021) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2021.01.037 · Cited by 19
Current scenario of COVID-19 vaccinations and immune response along with antibody titer in vaccinated inhabitants of different countries
Hussain, A., Rafeeq, H., Asif, H. M., Shabbir, S., Bilal, M., Mulla, S. I., Franco, M., & Iqbal, H. M. N. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.108050 · Cited by 20
Determination of neutralising anti-SARS-CoV-2 antibody half-life in COVID-19 convalescent donors
Barnes, T. W., Schulte-Pelkum, J., Steller, L., Filchtinski, D., Jenness, R., Williams, M. R., Kober, C., Manni, S., Hauser, T., Hahn, A., et al. (2021) · Clinical Immunology · doi:10.1016/j.clim.2021.108871 · Cited by 21
Longitudinally monitored immune biomarkers predict the timing of COVID-19 outcomes
Lasso, G., Khan, S. M., Allen, S. A., Mariano, M. C., Florez, C., Orner, E. P., Quiroz, J. A., Quevedo, G., Massimi, A. B., Hegde, A., et al. (2022) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1009778 · Cited by 21
Global trends in COVID-19
Zhou, C., Qin, X., Yan, L., Jiang, Y., & Yu, X. (2022) · Infectious Medicine · doi:10.1016/j.imj.2021.08.001 · Cited by 21
SARS-CoV-2 variant B.1.1.7 caused HLA-A2+ CD8+ T cell epitope mutations for impaired cellular immune response
Xiao, C., Mao, L., Wang, Z., Gao, L., Zhu, G., Su, J., Chen, X., Yuan, J., Hu, Y., Yin, Z., et al. (2022) · iScience · doi:10.1016/j.isci.2022.103934 · Cited by 21
SARS‐CoV‐2 specific antibody responses in healthcare workers after a third booster dose of CoronaVac or BNT162b2 vaccine
Yavuz, E., Günal, Ö., Başbulut, E., & Şen, A. (2022) · Journal of Medical Virology · doi:10.1002/jmv.27794 · Cited by 19
“It was shown that neutralizing antibody responses after natural infection declines over time.(9) Recently, a preliminary study from Israel assessed the correlation between the time from the BNT162b2 (Pfizer‐BioNTech) vaccine and the incidence of breakthrough infections and found that the risk for infection was signifi…”
Background
Tissue immunity to SARS‐CoV‐2: Role in protection and immunopathology*
Rybkina, K., Davis‐Porada, J., & Färber, D. L. (2022) · Immunological Reviews · doi:10.1111/imr.13112 · Cited by 19
Infection by SARS‐CoV‐2 with alternate frequencies of mRNA vaccine boosting
Townsend, J. P., Hassler, H. B., & Dornburg, A. (2023) · Journal of Medical Virology · doi:10.1002/jmv.28461 · Cited by 22
SARS-CoV-2 infection establishes a stable and age-independent CD8+ T cell response against a dominant nucleocapsid epitope using restricted T cell receptors
Choy, C., Chen, J., Li, J., Gallagher, D. T., Lü, J., Wu, D., Zou, A., Hemani, H., Baptiste, B. A., Wichmann, E., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-42430-z · Cited by 21
“As previously reported 50 , we observed a signi ﬁ cant decline of anti-nucleocapsid protein antibody titers in the blood, with a decay rate of − 0.012 AU/mL per day ( p = 0.001) (Fig.”
Influential
Longitudinal detection of SARS‐CoV‐2‐specific antibody responses with different serological methods
Emmerich, P., von Possel, R., Hemmer, C. J., Fritzsche, C., Geerdes-Fenge, H. F., Menge, B., Messing, C., Borchardt‐Lohölter, V., Deschermeier, C., & Steinhagen, K. (2021) · Journal of Medical Virology · doi:10.1002/jmv.27113 · Cited by 19
“Usually, specific immunoglobulin M (IgM) and immunoglobulin A (IgA) antibodies are detectable earlier than specific immunoglobulin G (IgG) antibodies.(5,7,8) In individual cases, anti‐ SARS‐CoV‐2 antibodies are either only detectable more than four weeks after onset of symptoms or not at all due to generally absent an…”
Background
Semi-quantitative, high throughput analysis of SARS-CoV-2 neutralizing antibodies: Measuring the level and duration of immune response antibodies post infection/vaccination
Taylor, S. C., Hurst, B., Martiszus, I., Hausman, M. S., Sarwat, S., Schapiro, J. M., Rowell, S., & Lituev, A. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.07.098 · Cited by 18
Development of SARS-CoV2 humoral response including neutralizing antibodies is not sufficient to protect patients against fatal infection
Choteau, M., Scohy, A., Messe, S., Luyckx, M., Dechamps, M., Montiel, V., Yombi, J. C., Gruson, D., Limaye, N., Michiels, T., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-06038-5 · Cited by 19
Functional SARS-CoV-2-sperific immune memory persists after mild COVID-19Preprint
Rodda, L., Netland, J., Shehata, L., Pruner, K., Morawski, P., Thouvenel, C., Takehara, K., Eggenberger, J., Hemann, E. A., Waterman, H., et al. (2020) · Research Square · doi:10.21203/rs.3.rs-57112/v1 · Cited by 237
Assessment of Risks Associated With Severe Acute Respiratory Syndrome Coronavirus 2 Experimental Human Infection Studies
Kuiper, V. P., Rosendaal, F. R., Kamerling, I. M. C., Visser, L. G., & Roestenberg, M. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa1784 · Cited by 20
COVID-19 seroprevalence in military police force, Southern Brazil
Pasqualotto, A. C., Pereira, P. D. C., Lana, D. F. D., Schwarzbold, A. V., Ribeiro, M., Riche, C. V. W., Castro, C. P. P., Korsack, P. L., Ferreira, P. E. B., Domingues, G. D. C., et al. (2021) · PLoS ONE · doi:10.1371/journal.pone.0249672 · Cited by 24
Safety and humoral responses to BNT162b2 mRNA vaccination of SARS-CoV-2 previously infected and naive populations
Efrati, S., Catalogna, M., Hamad, R. A., Hadanny, A., Bar‐Chaim, A., Benveniste‐Levkovitz, P., & Levtzion‐Korach, O. (2021) · Scientific Reports · doi:10.1038/s41598-021-96129-6 · Cited by 19
Persistence of immunity to SARS-CoV-2 over time in the ski resort Ischgl
Borena, W., Bánki, Z., Bates, K., Winner, H., Riepler, L., Rössler, A., Pipperger, L., Theurl, I., Falkensammer, B., Ulmer, H., et al. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103534 · Cited by 18
“Our study extends the previous research in three important ways: First, we con ﬁ rm that immunity as de ﬁ ned by T cell and/or neutralizing antibody response lasts for up to several months and that T cell and antibody responses can be discordant [8 (cid:1) 14,26].”
Influential
Original antigenic sin responses to Betacoronavirus spike proteins are observed in a mouse model, but are not apparent in children following SARS-CoV-2 infection
Lapp, S. A., Edara, V. V., Lu, A., Lai, L., Hussaini, L., Chahroudi, A., Anderson, L. J., Suthar, M. S., Anderson, E. J., & Rostad, C. A. (2021) · PLoS ONE · doi:10.1371/journal.pone.0256482 · Cited by 18
“3 days POS with a wide range (range 3–59 days) [14], and these factors are likely reflected in our results.”
Background
Reinfections in COVID-19 Patients: Impact of Virus Genetic Variability and Host Immunity
Fakhroo, A. D., Al-Khatib, H. A., Thani, A. A. A., & Yassine, H. M. (2021) · Vaccines · doi:10.3390/vaccines9101168 · Cited by 21
Antibody Dynamics and Durability in Coronavirus Disease-19
Zuiani, A., & Wesemann, D. R. (2021) · Clinics in Laboratory Medicine · doi:10.1016/j.cll.2021.10.004 · Cited by 19
Long-term immunologic effects of SARS-CoV-2 infection: leveraging translational research methodology to address emerging questions
Peluso, M. J., Donatelli, J. L., & Henrich, T. J. (2021) · Translational research · doi:10.1016/j.trsl.2021.11.006 · Cited by 18
Persistence of SARS-CoV-2-Specific Antibodies for 13 Months after Infection
Kučinskaitė-Kodzė, I., Simanavičius, M., Šimaitis, A., & Žvirblienė, A. (2021) · Viruses · doi:10.3390/v13112313 · Cited by 19
Quantifying Neutralizing Antibodies in Patients with COVID-19 by a Two-Variable Generalized Additive Model
Liu, K., Gong, Y., Huang, C., Huang, P.-N., Yu, K.-Y., Lee, H.-C., Lee, S.-C., Chiang, H.-J., Kung, Y.-A., Lin, Y., et al. (2022) · mSphere · doi:10.1128/msphere.00883-21 · Cited by 19
“The actual decrease was also dependent on the severity of the disease in the patients (26).”
Background
Making COVID-19 mRNA vaccines accessible: challenges resolved
Niazi, S. K. (2022) · Expert Review of Vaccines · doi:10.1080/14760584.2022.2089121 · Cited by 19
“For example, anti-SARS-CoV-2 T cells may be necessary since neutralizing antibodies wane over time [11,12].”
Background
Work performance among healthcare workers with post COVID-19 syndrome and its relation to antibody response
Fouad, M. M., Zawilla, N. H., & Maged, L. A. (2022) · Infection · doi:10.1007/s15010-022-01942-4 · Cited by 19
Humoral immunity and B-cell memory in response to SARS-CoV-2 infection and vaccination
Fryer, H. A., Hartley, G. E., Edwards, E. S. J., O’Hehir, R. E., & van Zelm, M. C. (2022) · Biochemical Society Transactions · doi:10.1042/bst20220415 · Cited by 16
The receptor binding domain of SARS-CoV-2 Omicron subvariants targets Siglec-9 to decrease its immunogenicity by preventing macrophage phagocytosis
He, X., Zhang, X., Wu, B., Deng, J., Zhang, Y., Zhu, A., Yuan, Y., Lin, Y., Chen, A., Feng, J., et al. (2024) · Nature Immunology · doi:10.1038/s41590-024-01776-2 · Cited by 20
“However, the unprecedented spread of the virus still poses a serious threat to public health 7,8 .”
Single-Dilution COVID-19 Antibody Test with Qualitative and Quantitative Readouts
Bortz, R. H., Florez, C., Laudermilch, E., Wirchnianski, A. S., Lasso, G., Malonis, R. J., Georgiev, G. I., Vergnolle, O., Herrera, N. G., Morano, N. C., et al. (2021) · mSphere · doi:10.1128/msphere.00224-21 · Cited by 20
Antibody (Serology) Tests for COVID-19: a Case Study
West, R. M., Kobokovich, A. L., Connell, N. D., & Grönvall, G. K. (2021) · mSphere · doi:10.1128/msphere.00201-21 · Cited by 19
“which form 7 to 10 or more days after initial infection (3, 4).”
Background
High avidity of vaccine-induced immunoglobulin G against SARS-CoV-2: potential relevance for protective humoral immunity
Bauer, G. (2022) · Exploration of Immunology · doi:10.37349/ei.2022.00040 · Cited by 19
“What might then be the overall benefit derived from the generation of immune cells that allow generating high avidity IgG directed towards critical viral surface structures? As the IgG responses towards SARS-CoV-2 are waning after natural infection, as well as after vaccination [103, 104], reinfection might be facilit…”
Background
Analysis of a SARS-CoV-2 convalescent cohort identified a common strategy for escape of vaccine-induced anti-RBD antibodies by Beta and Omicron variants
Chang, M., Ke, H., Coherd, C. D., Wang, Y., Mashima, K., Kastrunes, G. M., Huang, C., & Marasco, W. A. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.104025 · Cited by 20
Potent neutralizing equine antibodies raised against recombinant SARS-CoV-2 spike protein for COVID-19 passive immunization therapyPreprint
da Cunha, L. E. R., Stolet, A. A., Strauch, M. A., Pereira, V. A. R., Dumard, C. H., Gomes, A. M. O., Souza, P. N. C., Fonseca, J. G. D. S., de Pontes, F. E., Meirelles, L. G. R., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.08.17.254375 · Cited by 21
Immunogenicity of novel mRNA COVID-19 vaccine MRT5500 in mice and non-human primates
Kalnin, K. V., Plitnik, T., Kishko, M., Zhang, J., Zhang, D., Beauvais, A., Anosova, N. G., Tibbitts, T., DiNapoli, J. M., Huang, P.-W. D., et al. (2020) · doi:10.1101/2020.10.14.337535 · Cited by 18
Laboratory diagnosis of severe acute respiratory syndrome coronavirus 2
Gulholm, T., Basile, K., Kok, J., Chen, S. C.-A., & Rawlinson, W. D. (2020) · Pathology · doi:10.1016/j.pathol.2020.09.011 · Cited by 18
Titers of Neutralizing Antibodies against SARS-CoV-2 Are Independent of Symptoms of Non-Severe COVID-19 in Young Adults
Jónsdóttir, H. R., Bielecki, M., Siegrist, D., Buehrer, T. W., Züst, R., & Deuel, J. (2021) · Viruses · doi:10.3390/v13020284 · Cited by 17
“Thus, antibody titers seem to be determined by disease severity and not duration, with varied numbers of asymptomatic cases having been reported to produce nAbs [24].”
Background
SARS-CoV-2 Antibody Binding and Neutralization in Dried Blood Spot Eluates and Paired Plasma
Itell, H. L., Weight, H., Fish, C. S., Logue, J. K., Franko, N., Wolf, C. R., McCulloch, D. J., Galloway, J., Matsen, F. A., IV, Chu, H. Y., et al. (2021) · Microbiology Spectrum · doi:10.1128/spectrum.01298-21 · Cited by 18
“(3) Cohort-level agreement between sample types was evaluated by”
Background
Resistance of SARS-CoV-2 variants to neutralization by convalescent plasma from early COVID-19 outbreak in Singapore
Wang, B., Goh, Y. S., Prince, T., Ngoh, E. Z. X., Salleh, S. N. M., Hor, P. X., Loh, C. Y., Fong, S., Hartley, C. S., Tan, S. Y., et al. (2021) · npj Vaccines · doi:10.1038/s41541-021-00389-2 · Cited by 19
SARS-CoV-2 Spike Expression at the Surface of Infected Primary Human Airway Epithelial Cells
Ding, S., Adam, D., Beaudoin-Bussières, G., Tauzin, A., Gong, S. Y., Gasser, R., Laumaea, A., Anand, S. P., Privé, A., Bourassa, C., et al. (2021) · Viruses · doi:10.3390/v14010005 · Cited by 18
Pandemic, Epidemic, Endemic: B Cell Repertoire Analysis Reveals Unique Anti-Viral Responses to SARS-CoV-2, Ebola and Respiratory Syncytial Virus
Stewart, A., Sinclair, E. L., Ng, J. C.-F., O’Hare, J. S., Page, A., Serangeli, I., Margreitter, C., Orsenigo, F., Longman, K., Frampas, C., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.807104 · Cited by 18
Serological antibody testing in the COVID-19 pandemic: their molecular basis and applications
Jiang, J.-C., & Zhang, Y. (2020) · Biochemical Society Transactions · doi:10.1042/bst20200744 · Cited by 19
IgM and IgG Profiles Reveal Peculiar Features of Humoral Immunity Response to SARS-CoV-2 Infection
Donno, A. D., Lobreglio, G., Panìco, A., Grassi, T., Bagordo, F., Bozzetti, M. P., Massari, S., Siculella, L., Damiano, F., Guerra, F., et al. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18031318 · Cited by 21
Two-tiered SARS-CoV-2 seroconversion screening in the Netherlands and stability of nucleocapsid, spike protein domain 1 and neutralizing antibodies
Garritsen, A., Scholzen, A., van den Nieuwenhof, D. W. A., Smits, A. P. F., Datema, E. S., van Galen, L. S., & Kouwijzer, M. (2021) · Scandinavian Journal of Infectious Diseases · doi:10.1080/23744235.2021.1893378 · Cited by 15
“Overall, IgM and IgA antibody responses against SARS-CoV-2 RBD, S1 and NCP appear to contract rapidly, while circulating antiSARS-CoV-2 IgG directed against these antigens remain much more stable [23,25,29].”
Background
Association between self-reported signs and symptoms and SARS-CoV-2 antibody detection in UK key workers
Mulchandani, R., Taylor-Philips, S., Jones, H. E., Ades, A. E., Borrow, R., Linley, E., Kirwan, P., Stewart, R., Moore, P., Boyes, J., et al. (2021) · Journal of Infection · doi:10.1016/j.jinf.2021.03.019 · Cited by 18
Sustained Neutralizing Antibodies 6 Months Following Infection in 376 Japanese COVID-19 Survivors
Goto, A., Go, H., Miyakawa, K., Yamaoka, Y., Ohtake, N., Kubo, S., Jeremiah, S. S., Mihara, T., Senuki, K., Miyazaki, T., et al. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.661187 · Cited by 18
“This decline in neutralizing antibodies at a relatively early phase of infection has been consistently reported in many studies with varieties of populations (Crawford et al., 2020; Gaebler et al., 2020; Ibarrondo et al., 2020; Kutsuna et al., 2020; Long et al., 2020; Patel et al., 2020; Ripperger et al., 2020; Seow e…”
BackgroundMethodResultInfluential
Tissue-resident memory CD8 T-cell responses elicited by a single injection of a multi-target COVID-19 vaccinePreprint
Gauttier, V., Morello, A., Girault, I., Mary, C., Belarif, L., Desselle, A., Wilhelm, E., Bourquard, T., Pengam, S., Teppaz, G., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.08.14.240093 · Cited by 18
COVID-19 transmission in a university setting: a rapid review of modelling studiesPreprint
Christensen, H., Turner, K., Trickey, A., Booton, R. D., Hemani, G., Nixon, E. J., Relton, C. L., Danon, L., Hickman, M., & Brooks‐Pollock, E. (2020) · medRxiv · doi:10.1101/2020.09.07.20189688 · Cited by 18
Decay of Fc-dependent antibody functions after mild to moderate COVID-19
Lee, W. S., Selva, K. J., Davis, S. K., Wines, B. D., Reynaldi, A., Esterbauer, R., Kelly, H. G., Haycroft, E. R., Tan, H.-X., Juno, J. A., et al. (2020) · doi:10.1101/2020.12.13.20248143 · Cited by 80
RETRACTED: Understanding the implications of SARS-CoV-2 re-infections on immune response milieu, laboratory tests and control measures against COVID-19
Mustapha, J. O., Abdullahi, I. N., Ajagbe, O., Emeribe, A. U., Fasogbon, S. A., Onoja, S. O., Ugwu, C. E., Umeozuru, C. M., Ajayi, F. O., Tanko, W. N., et al. (2021) · Heliyon · doi:10.1016/j.heliyon.2021.e05951 · Cited by 17
Retracted
SARS-CoV-2 virus: Vaccines in development
Huang, Q., & Yan, J. (2021) · Fundamental Research · doi:10.1016/j.fmre.2021.01.009 · Cited by 18
A review of COVID-19 convalescent plasma use in COVID-19 with focus on proof of efficacy
Devarasetti, P. K., Rajasekhar, L., Baisya, R., Sreejitha, K. S., & Vardhan, Y. K. (2021) · Immunologic Research · doi:10.1007/s12026-020-09169-x · Cited by 17
Antibody kinetics and clinical course of COVID-19 a prospective observational study
Bläckberg, A., Fernström, N., Sarbrant, E., Rasmussen, M., & Sunnerhagen, T. (2021) · PLoS ONE · doi:10.1371/journal.pone.0248918 · Cited by 18
“Seow et al reported an average higher titer of neutralizing antibodies in patients with severe COVID-19, however no correlation of antibody kinetics was established [11].”
Background
Anti-Spike SARS-CoV-2 IgG Assessment with a Commercial Assay during a 4-Month Course after COVID-19 Vaccination
Swadźba, J., Anyszek, T., Panek, A., & Martin, E. (2021) · Vaccines · doi:10.3390/vaccines9111367 · Cited by 17
Coordinated innate and T-cell immune responses in mild COVID-19 patients from household contacts of COVID-19 cases during the first pandemic wave
Aiello, A., Grossi, A., Meschi, S., Meledandri, M., Vanini, V., Petrone, L., Casetti, R., Cuzzi, G., Salmi, A., Altera, A. M. G., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.920227 · Cited by 18
“Age median (IQR) 48 (29-55) 58 (52-71) 42 (38-54) <0.”
Background
High SARS-CoV-2 seroprevalence in Karaganda, Kazakhstan before the launch of COVID-19 vaccination
Kadyrova, I., Yegorov, S., Negmetzhanov, B., Kolesnikova, Y. A., Kolesnichenko, S. I., Korshukov, I., Akhmaltdinova, L., Vazenmiller, D., Stupina, Y., Амирбековна, К. Н., et al. (2022) · PLoS ONE · doi:10.1371/journal.pone.0272008 · Cited by 17
Can live-attenuated SARS-CoV-2 vaccine contribute to stopping the pandemic?
Tang, P. C. H., Ng, W. H., King, N. J. C., & Mahalingam, S. (2022) · PLoS Pathogens · doi:10.1371/journal.ppat.1010821 · Cited by 18
“In general, disease severity enhanced these responses [12], as has previously been observed [13,14].”
Result
Persistent but dysfunctional mucosal SARS-CoV-2-specific IgA and low lung IL-1β associate with COVID-19 fatal outcome: A cross-sectional analysis
Ruiz, M. J., Siracusano, G., Cottignies-Calamarte, A., Tudor, D., Real, F., Zhu, A., Pastori, C., Capron, C., Rosenberg, A. R., Temperton, N. J., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.842468 · Cited by 21
“Outcome Survivor Non-survivor 7 (64) 4 (36) 14 (61) 9 (39) 21 (100) 0 (0) 42 (76) 13 (24)”
BackgroundSelf-citation
The effect of Omicron breakthrough infection and extended BNT162b2 booster dosing on neutralization breadth against SARS-CoV-2 variants of concern
Graham, C., Lechmere, T., Rehman, A., Seow, J., Kurshan, A., Huettner, I., Maguire, T. J. A., Tam, J. C. H., Cox, D., Ward, C. C., et al. (2022) · PLoS Pathogens · doi:10.1371/journal.ppat.1010882 · Cited by 14
“14 Recombinant Spike and nucleoprotein for ELISA were expressed and purified as 337 previously described [17, 53].”
BackgroundMethodSelf-citation
Portable Surface Plasmon Resonance Detector for COVID-19 Infection
Trzaskowski, M., Mazurkiewicz-Pisarek, A., Trzciński, J., Drozd, M., Podgórski, R., ZABOST, A. T., & AUGUSTYNOWICZ-KOPEĆ, E. M. (2023) · Sensors · doi:10.3390/s23083946 · Cited by 17
Infants and young children generate more durable antibody responses to SARS-CoV-2 infection than adults
Joshi, D., Nyhoff, L. E., Zarnitsyna, V. I., Moreno, A., Manning, K. E., Linderman, S. L., Burrell, A. R., Stephens, K., Norwood, C., Mantus, G. E., et al. (2023) · iScience · doi:10.1016/j.isci.2023.107967 · Cited by 17
“23 It is well established that the loss of binding titers results in a coordinated loss of neutralization titer (Figure 5A), 16,24–26 most likely due to the strong correlation between spike and RBD-binding titers and neutralization (Figure 5B), 11,27 indicating that fraction of anti-spike/RBD IgG…”
The challenges of COVID-19 in the Brazilian Amazonian communities and the importance of seroepidemiological surveillance studies
Vallinoto, A. C. R., Torres, M. K. D. S., Vallinoto, M. C., & Vallinoto, I. M. V. C. (2020) · International Journal for Equity in Health · doi:10.1186/s12939-020-01256-7 · Cited by 17
Covid-19 transmission modelling of students returning home from university
Harper, P., Moore, J. W., & Woolley, T. E. (2021) · Health Systems · doi:10.1080/20476965.2020.1857214 · Cited by 17
“However, questions regarding how long the immunity will last (Ripperger et al. 2020, Tan et al. 2020, Callow et al. 1990, Seow et al. 2020) coupled with suﬀering through the actual disease and the stress of missing coursework (Husky et al. 2020) leads this to be an unsympathetic plan of action.”
Background

Authors: Seow, J., Graham, C., Merrick, B., Acors, S., Pickering, S., Steel, K. J. A., Hemmings, O., O’Byrne, A., Kouphou, N., Galao, R. P., Betancor, G., Wilson, H. D., Signell, A. W., Winstone, H., Kerridge, C., Huettner, I., Jimenez-Guardeño, J. M., Lista, M. J., Temperton, N., Snell, L. B., Bisnauthsing, K., Moore, A., Green, A., Martinez, L., Stokes, B., Honey, J., Izquierdo-Barras, A., Arbane, G., Patel, A., Tan, M. K. I., O’Connell, L., O’Hara, G., MacMahon, E., Douthwaite, S., Nebbia, G., Batra, R., Martinez-Nunez, R., Shankar-Hari, M., Edgeworth, J. D., Neil, S. J. D., Malim, M. H., & Doores, K. J.
Affiliations: King's College London (GB)
Guy's Hospital (GB)
Medway School of Pharmacy (GB)
Guy's and St Thomas' NHS Foundation Trust (GB)
Corresponding author: Doores, Katie J.
ORCID: Seow, Jeffrey
Merrick, Blair
Acors, Sam
Pickering, Suzanne
Steel, Kathryn J. A.
Hemmings, Oliver
O’Byrne, Aoife
Kouphou, Neophytos
Galao, Rui Pedro
Betancor, Gilberto
Wilson, Harry D.
Signell, Adrian W.
Winstone, Helena
Jimenez-Guardeño, Jose M.
Temperton, Nigel
Snell, Luke B.
Bisnauthsing, Karen
Martinez, Lauren
Stokes, Brielle
Izquierdo-Barras, Alba
Patel, Amita
Tan, Mark Kia Ik
O’Connell, Lorcan
O’Hara, Geraldine
Douthwaite, Sam
Nebbia, Gaia
Batra, Rahul
Shankar-Hari, Manu
Edgeworth, Jonathan D.
Neil, Stuart J. D.
Malim, Michael H.
Doores, Katie J.
Venue: Nature Microbiology
Publisher: Springer Science and Business Media LLC
Published: 2020-10-26
Volume: 5
Issue: 12
Pages: 1598-1607
ISSN: 2058-5276 (ISSN-L)
DOI: 10.1038/s41564-020-00813-8
PMC: PMC7610833
OpenAlex: W3093667122
Cited by: 1,419
References: 62
Citations by year: 2026: 18 · 2025: 44 · 2024: 75 · 2023: 147 · 2022: 311 · 2021: 615 · 2020: 207
FWCI: 41.93
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.springernature.com/gp/researchers/text-and-data-mining (tdm)
www.springernature.com/gp/researchers/text-and-data-mining (vor)
Locations: Nature Microbiology (publishedVersion)
medRxiv (acceptedVersion, cc-by-nc-nd)
PubMed (publishedVersion)
Pure Amsterdam UMC (publishedVersion, other-oa)
Kent Academic Repository (University of Kent) (acceptedVersion)
PubMed Central (acceptedVersion)
Data Archiving and Networked Services (DANS) (submittedVersion)
Research Portal (King's College London) (submittedVersion, other-oa)
Repositorio Institucional de la Universidad de Málaga (University of Málaga) (submittedVersion, cc-by-nc-nd)
Funders: RCUK | Medical Research Council (MC/PC/15068, MR/N013700/1, MR/R015643/1, MC/PC/15068, MR/R015643/1, MR/S023747/1)
Huo Family Foundation
Wellcome Trust (WT098049AIA, MR/S023747/1, 106223/Z/14/Z)
Huo Family Foundation King’s Together Rapid COVID-19 Call award
DH | National Institute for Health Research (CS-2016-16-011)
King’s Together Rapid COVID-19 Call award Huo Family Foundation
Fondation Dormeur, Vaduz King’s Together Rapid COVID-19 Call award Huo Family Foundation
Topics: Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 detection and testing
Keywords: SARS-CoV-2, COVID-19 pandemic, neutralizing antibodies, antibody waning, seroconversion, antibody kinetics, disease severity, infectious dose, reinfection protection, healthcare workers, booster vaccination, serological testing
MeSH terms: Seroconversion, COVID-19, SARS-CoV-2, Adult, Aged, Aged, 80 and over, Antibodies, Viral, Female, Humans, Kinetics, Longitudinal Studies, Male, Middle Aged, Severity of Illness Index, Young Adult, Antibodies, Neutralizing

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks